(AOF) – Following the publication of our latest dispatch on ResMed, the company wished to provide several clarifications. It indicates that its brand’s magnet masks “are not the subject of a recall but more simply of an update of the instructions concerning interference, when the magnet masks are near implanted medical devices ( e.g. pacemakers, implantable cardioverter defibrillators (ICDs), neurostimulators, cerebrospinal fluid (CSF) shunts, insulin or infusion pumps).”
She adds that the term “recall” used by the FDA represents different situations, including product recall. “However, the notion of recall in French can easily lead to confusion, because it is very often understood as implying a withdrawal of products. In this case, it is an update of contraindications and warnings of these masks with magnets”, emphasizes ResMed.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.